New drug cocktail aims to wipe out esophageal cancer before surgery
NCT ID NCT07490002
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) and a targeted therapy (lenvatinib) to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The main goal is to see how many patients have no cancer cells left in their surgical specimen (pathological complete response). The study will enroll 33 participants and is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iparomlimab, tuvonralimab, lenvatinib, cisplatin/carboplatin, nab-paclitaxel
- What this could lead to
- If successful, this could lead to a more effective pre-surgery treatment for esophageal cancer, potentially increasing the chance of eliminating all cancer before surgery.
- What could go wrong
- This is a small, early-phase study (33 people) with no control group, so results may not be definitive. The drug combination may cause significant side effects and may not improve outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.